Cogent Biosciences Financial Statements
NASDAQ: COGTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
31.00+0.92 (+3.06%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Cogent Biosciences revenue and earnings
Cogent Biosciences reported a net loss of $328.9 million, compared with a loss of $255.9 million a year earlier. Diluted earnings per share came in at -$2.16.
Summary generated from market data by MetaCap's automated system. Methodology
Cogent Biosciences income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | 7.87M | 22.50M | 9.73M | 8.36M |
| Revenue growth (YoY) | — | — | — | — | — | -65.02% | +131.14% | +16.44% | — |
| Research & Development | 269.78M | 232.66M | 173.75M | 121.63M | 55.91M | 25.74M | 43.71M | 38.28M | 29.83M |
| Operating Income | -333.36M | -275.94M | -208.13M | -147.84M | -75.55M | -82.20M | -32.18M | -36.01M | -26.15M |
| Interest Expense | 3.06M | — | — | — | — | — | — | — | — |
| Other Income (Expense) | 4.43M | 20.08M | 15.72M | 7.60M | 3.28M | 7.39M | 345.00K | 1.47M | 660.00K |
| Income Tax | 0 | — | — | — | — | — | — | — | — |
| Net Income | -328.94M | -255.86M | -192.41M | -140.24M | -72.27M | -74.81M | -31.83M | -34.53M | -25.49M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -2.16 | -1.94 | -1.94 | -1.73 | -1.87 | -16.17 | -4.18 | -1.39 | -2.51 |
| EPS (Diluted) | -2.16 | -1.94 | -1.94 | -1.73 | -1.87 | -16.17 | -4.18 | -1.39 | -2.51 |
| Shares Outstanding (Basic) | 128.90M | 103.86M | 79.66M | 58.74M | 38.73M | 11.08M | 7.62M | 24.90M | 10.19M |
| Shares Outstanding (Diluted) | 128.90M | 103.86M | 79.66M | 58.74M | 38.73M | 11.08M | 7.62M | 24.90M | 10.19M |
| EBITDA | -330.76M | -273.44M | -205.83M | -147.04M | -75.40M | -81.48M | -30.89M | -34.68M | -24.98M |
| Operating Margin | — | — | — | — | — | -1044.33% | -143.02% | -369.89% | -312.82% |
| Net Margin | — | — | — | — | — | -950.43% | -141.49% | -354.76% | -304.93% |
This table shows 9 annual periods of Cogent Biosciences's income statement, from FY 2025 back to FY 2017, across 14 line items including revenue, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow COGT's reporting calendar. What is a income statement?